More on the generic Epi-pen:
“In its latest move to quell public outrage over its price increases, Mylan Pharmaceuticals has agreed to sell a generic version of its EpiPen, used to treat severe allergic reactions, for $300 instead of the $600 of its brand-name version. $300 is still triple the price EpiPen was selling for when Mylan acquired it nine years ago.
When an extortionist agrees to halve what it’s demanding, it’s still extortion. Mylan has the monopoly power to charge what it likes. It’s the same problem in much of the pharmaceutical industry, where monopoly power has replaced competition. Which is why the industry must be subject either to antitrust enforcement or to regulation. Without either, consumers (and taxpayers) are getting socked with a huge and growing tab.”
(Robert Reich on the below article from the NYTimes).
http://www.nytimes.com/2016/08/30/business/mylan-generic-epipen.html
